Modality
Bispecific Ab
MOA
VEGFi
Target
SHP2
Pathway
Fibrosis
CLLFabryLGS
Development Pipeline
Preclinical
~Apr 2016
→ ~Jul 2017
Phase 1
~Oct 2017
→ ~Jan 2019
Phase 2
~Apr 2019
→ ~Jul 2020
Phase 3
Oct 2020
→ Nov 2028
Phase 3Current
NCT06720584
256 pts·LGS
2022-03→2028-07·Not yet recruiting
NCT06900787
330 pts·LGS
2020-10→TBD·Recruiting
NCT06921393
1,882 pts·Fabry
2024-03→2028-08·Completed
+1 more trial
3,984 total pts2 indications
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (3)
2028-07-162.3y awayPh3 Readout· LGS
2028-08-192.4y awayPh3 Readout· Fabry
2028-11-282.7y awayPh3 Readout· Fabry
Trial Timeline
Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q4
P3
Recruit…
P3
Not yet…
P3
Complet…
P3
Not yet…
Catalysts
Ph3 Readout
2028-07-16 · 2.3y away
LGS
Ph3 Readout
2028-08-19 · 2.4y away
Fabry
Ph3 Readout
2028-11-28 · 2.7y away
Fabry
RecruitingCompletedNot yet recruiting|StartCompletionToday
Trials (4)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT06720584 | Phase 3 | LGS | Not yet recr... | 256 | NT-proBNP |
| NCT06900787 | Phase 3 | LGS | Recruiting | 330 | BodyWt |
| NCT06921393 | Phase 3 | Fabry | Completed | 1882 | Biomarker |
| NCT03993033 | Phase 3 | Fabry | Not yet recr... | 1516 | CR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| NVS-5126 | Novartis | Phase 3 | SHP2 | |
| MRK-1380 | Merck & Co | Preclinical | SHP2 | |
| MRK-5413 | Merck & Co | Phase 1 | GLP-1R | |
| Doxasotorasib | AbbVie | Phase 2 | CD38 | |
| ABB-1817 | AbbVie | Phase 3 | SHP2 | |
| AZN-8281 | AstraZeneca | Phase 1 | SHP2 | |
| AZN-8478 | AstraZeneca | NDA/BLA | SHP2 | |
| Ceviderotide | Novo Nordisk | Preclinical | IL-13 | |
| VRT-6833 | Vertex Pharma | Preclinical | ALK | |
| MRN-7409 | Moderna | NDA/BLA | SHP2 |